A public–private partnership to enrich the development of in silico predictive models for pharmacokinetic and cardiotoxic properties
Hiroshi Komura, Reiko Watanabe, Hitoshi Kawashima, Rikiya Ohashi, Masataka Kuroda, Tomohiro Sato, Teruki Honma, Kenji Mizuguchi · Drug Discovery Today · 2021
A novel framework for a public-private (PP) partnership was established by a national initiative of the Development of a Drug Discovery Informatics System, supported by the Japan Agency for Medical Research and Development (AMED). This informatics PP partnership consortium comprised private and public sectors. A database of pharmacokinetic (PK) and cardiotoxic properties was developed, with considerable expansion after integrating proprietary data from private-sector members. This database led to robust in silico prediction models with higher performance than those from the original database. This partnership is a unique example worldwide and could substantially strengthen drug discovery capabilities in both sectors.